Sort by
Previous Page Page 1 of 9 Next Page
  1. Review

    Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation

    The challenge of providing access to high-priced patented medicines is a global problem affecting all countries. A decade and a half ago the use of flexibilities contained in the World Trade Organization Agree...

    Ellen F. M. ‘t Hoen, Pascale Boulet and Brook K. Baker

    Journal of Pharmaceutical Policy and Practice 2017 10:19

    Published on: 28 June 2017

  2. Research

    Promoting transparency, accountability, and access through a multi-stakeholder initiative: lessons from the medicines transparency alliance

    Barriers to expanding access to medicines include weak pharmaceutical sector governance, lack of transparency and accountability, inadequate attention to social services on the political agenda, and financing ...

    Taryn Vian, Jillian C. Kohler, Gilles Forte and Deirdre Dimancesco

    Journal of Pharmaceutical Policy and Practice 2017 10:18

    Published on: 2 June 2017

  3. Research

    Comparison of medicines management strategies in insurance schemes in middle-income countries: four case studies

    Many middle-income countries are scaling up health insurance schemes to provide financial protection and access to affordable medicines to poor and uninsured populations. Although there is a wealth of evidence...

    Warren A. Kaplan, Paul G. Ashigbie, Mohamad I. Brooks and Veronika J. Wirtz

    Journal of Pharmaceutical Policy and Practice 2017 10:17

    Published on: 16 May 2017

  4. Research

    Individual capacity-building approaches in a global pharmaceutical systems strengthening program: a selected review

    Medicines use related challenges such as inadequate adherence, high levels of antimicrobial resistance and preventable adverse drug reactions have underscored the need to incorporate pharmaceutical services to...

    Niranjan Konduri, Megan Rauscher, Shiou-Chu Judy Wang and Tanya Malpica-Llanos

    Journal of Pharmaceutical Policy and Practice 2017 10:16

    Published on: 8 May 2017

  5. Research

    Two years post affordable medicines facility for malaria program: availability and prices of anti-malarial drugs in central Ghana

    The Affordable Medicines Facility for malaria (AMFm) Program was a subsidy aimed at artemisinin-based combination therapies (ACTs) in order to increase availability, affordability, and market share of ACTs in ...

    Alexander Freeman, Anthony Kwarteng, Lawrence Gyabaa Febir, Seeba Amenga-Etego, Seth Owusu-Agyei and Kwaku Poku Asante

    Journal of Pharmaceutical Policy and Practice 2017 10:15

    Published on: 28 April 2017

  6. Policy Analysis

    Drug pricing and reimbursement decision making systems in Mongolia

    It is essential to allocate available resources equitably in order to ensure accessibility and affordability of essential medicines, especially in less fortunate nations with limited health funding. Currently,...

    Gereltuya Dorj, Bruce Sunderland, Tsetsegmaa Sanjjav, Gantuya Dorj and Byambatsogt Gendenragchaa

    Journal of Pharmaceutical Policy and Practice 2017 10:11

    Published on: 27 February 2017

  7. Commentary

    The changing landscape of expanded access to investigational drugs for patients with unmet medical needs: ethical implications

    When patients are told that standard medical treatment options have been exhausted, their treating physicians may start looking for promising new drugs that are not yet approved, and still under investigation....

    Eline M. Bunnik, Nikkie Aarts and Suzanne van de Vathorst

    Journal of Pharmaceutical Policy and Practice 2017 10:10

    Published on: 21 February 2017

  8. Research

    Capacity for ethical and regulatory review of herbal trials in developing countries: a case study of Moringa oleifera research in HIV-infected patients

    Lack of regulatory capacity limits the conduct of ethical and rigorous trials of herbal medicines in developing countries. Sharing ethical and regulatory experiences of successful herbal trials may accelerate ...

    Tsitsi G. Monera-Penduka, Charles C. Maponga, Gene D. Morse and Charles F. B. Nhachi

    Journal of Pharmaceutical Policy and Practice 2017 10:9

    Published on: 20 February 2017

  9. Research

    Approval status and evidence for WHO essential medicines for children in the United States, United Kingdom, and Japan: a cross-sectional study

    The WHO Model List of Essential Medicines for Children (EMLc) covers medicines for globally high-burden diseases. Regulatory approval in high-income countries ensures evidence and dosage form but usually focus...

    Rumiko Shimazawa and Masayuki Ikeda

    Journal of Pharmaceutical Policy and Practice 2017 10:4

    Published on: 6 January 2017

  10. Research

    Civil society engagement in multi-stakeholder dialogue: a qualitative study exploring the opinions and perceptions of MeTA members

    The Medicines Transparency Alliance (MeTA) is an initiative that brings together all stakeholders in the medicines market to create a multi-stakeholder dialogue and improve access, availability and affordabili...

    Gemma L. Buckland-Merrett, Catherine Kilkenny and Tim Reed

    Journal of Pharmaceutical Policy and Practice 2017 10:5

    Published on: 6 January 2017

  11. Research

    The choice between a ritonavir-boosted protease inhibitor- and a non-nucleoside reverse transcriptase inhibitor-based regimen for initiation of antiretroviral treatment – results from an observational study in Germany

    This study aims at identifying predictors of the treatment decision of German physicians with regard to a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI/r)...

    Jörg Mahlich, Mona Groß, Alexander Kuhlmann, Johannes Bogner, Hans Heiken and Matthias Stoll

    Journal of Pharmaceutical Policy and Practice 2016 9:39

    Published on: 30 December 2016

  12. Research

    Assessing medication packaging and labelling appropriateness in Sri Lanka

    There is substantial evidence of poor dispensing practices with inadequate packaging and labelling of medicines, and limited advice on their usage in low and middle-income countries (LMICs). We examined the la...

    N. Athuraliya, E. J. Walkom, S. Dharmaratne and J. Robertson

    Journal of Pharmaceutical Policy and Practice 2016 9:38

    Published on: 25 November 2016

  13. Commentary

    Fighting poor-quality medicines in low- and middle-income countries: the importance of advocacy and pedagogy

    The globalization of pharmaceutical production has not been accompanied by a strengthening and harmonization of the regulatory systems worldwide. Thus, the global market is characterized today by a situation o...

    Raffaella Ravinetto, Daniel Vandenbergh, Cécile Macé, Corinne Pouget, Brigitte Renchon, Jean Rigal, Benedetta Schiavetti and Jean-Michel Caudron

    Journal of Pharmaceutical Policy and Practice 2016 9:36

    Published on: 10 November 2016

  14. Short Report

    Impact of switching from intravenous to oral linezolid therapy in Japanese patients: a retrospective cohort study

    High oral bioavailability of antimicrobial agents can result in the replacement of intravenous (IV) therapy with oral therapy when a patient meets defined clinical criteria. However, few studies have evaluated...

    Akihiro Tanaka, Akiko Yano, Shinichi Watanabe, Mamoru Tanaka and Hiroaki Araki

    Journal of Pharmaceutical Policy and Practice 2016 9:35

    Published on: 28 October 2016

  15. Research

    An assessment of the future impact of alternative technologies on antibiotics markets

    The increasing threat of antimicrobial resistance combined with the paucity of new classes of antibiotics represents a serious public health challenge. New treatment technologies could, in theory, have a signi...

    Ejike Nwokoro, Ross Leach, Christine Årdal, Enrico Baraldi, Kellie Ryan and Jens Plahte

    Journal of Pharmaceutical Policy and Practice 2016 9:34

    Published on: 26 October 2016

  16. Editorial

    Medicine and the future of health: reflecting on the past to forge ahead

    The development of new therapies has a rich history, evolves quickly with societal trends, and will have an exciting future. The last century has seen an exponential increase in complex interactions between me...

    Dale Fisher, Paul Wicks and Zaheer-Ud-Din Babar

    Journal of Pharmaceutical Policy and Practice 2016 9:33

    Published on: 25 October 2016

  17. Research

    Impact of pharmacists as immunizers on influenza vaccination coverage in the community-setting in Nova Scotia, Canada: 2013-2015

    Annual immunization is the most effective way to prevent influenza and its associated complications. However, optimal immunization rates are not being met in Nova Scotia, Canada. Additional providers, such as ...

    Jennifer E. Isenor, Jessica L. Killen, Beverly A. Billard, Shelly A. McNeil, Donna MacDougall, Beth A. Halperin, Kathryn L. Slayter and Susan K. Bowles

    Journal of Pharmaceutical Policy and Practice 2016 9:32

    Published on: 19 October 2016

  18. Review

    Towards the just and sustainable use of antibiotics

    The emergence and spread of antibiotic resistant pathogens poses a big challenge to policy-makers, who need to oversee the transformation of health systems that evolved to provide easy access to these drugs in...

    Gemma L. Buckland Merrett, Gerald Bloom, Annie Wilkinson and Hayley MacGregor

    Journal of Pharmaceutical Policy and Practice 2016 9:31

    Published on: 7 October 2016

Previous Page Page 1 of 9 Next Page